These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 3144169)

  • 21. A symposium: The use of encainide in supraventricular tachycardias. June 3 and 4, 1988, Bermuda. Proceedings.
    Am J Cardiol; 1988 Dec; 62(19):1L-84L. PubMed ID: 3144162
    [No Abstract]   [Full Text] [Related]  

  • 22. Mortality in patients treated with flecainide and encainide for supraventricular arrhythmias.
    Pritchett EL; Wilkinson WE
    Am J Cardiol; 1991 May; 67(11):976-80. PubMed ID: 1902055
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New antiarrhythmic drugs: tocainide, mexiletine, flecainide, encainide, and amiodarone.
    Kreeger RW; Hammill SC
    Mayo Clin Proc; 1987 Nov; 62(11):1033-50. PubMed ID: 3118116
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Advances in the treatment of supraventricular tachycardia.
    Naccarelli GV; Wellens HJ
    Am J Cardiol; 1988 Dec; 62(19):1L-3L. PubMed ID: 3144161
    [No Abstract]   [Full Text] [Related]  

  • 25. Comparison of twice daily with thrice daily administered encainide for benign or potentially lethal ventricular arrhythmias.
    Hohnloser SH; Zabel M; Zehender M; Meinertz T; Just H
    Am J Cardiol; 1989 Jan; 63(1):73-6. PubMed ID: 2462343
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Encainide for refractory supraventricular tachycardia in children.
    Strasburger JF; Moak JP; Smith RT; McVey-Duncan P; Armstrong K; Garson A
    Am J Cardiol; 1986 Aug; 58(5):49C-54C. PubMed ID: 3092620
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Malignant ventricular tachyarrhythmias associated with the use of encainide.
    Winkle RA; Mason JW; Griffin JC; Ross D
    Am Heart J; 1981 Nov; 102(5):857-64. PubMed ID: 6795909
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Anti-arrhythmia effect of long-term encainide in chronic ventricular extrasystole].
    Dumoulin P; Jaillon P; Kher A; Poirier JM; Cheymol G; Valty J; Flammang D; Coumel P; Medvedowsky JL; Barnay C
    Arch Mal Coeur Vaiss; 1985 Oct; 78 Spec No():105-9. PubMed ID: 2420299
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Total suppression of ventricular arrhythmias by encainide. Pharmacokinetic and electrocardiographic characteristics.
    Roden DM; Reele SB; Higgins SB; Mayol RF; Gammans RE; Oates JA; Woosley RL
    N Engl J Med; 1980 Apr; 302(16):877-82. PubMed ID: 6767186
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Electrophysiology in assessing supraventricular arrhythmias: value of programmed stimulation in predicting and understanding efficacy of encainide.
    Wellens HJ; Brugada P
    Am J Cardiol; 1986 Aug; 58(5):37C-40C. PubMed ID: 3092617
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical efficacy and electrophysiologic effects of intravenous and oral encainide in patients with accessory atrioventricular pathways and supraventricular arrhythmias.
    Abdollah H; Brugada P; Green M; Wehr M; Wellens HJ
    Am J Cardiol; 1984 Sep; 54(6):544-9. PubMed ID: 6433688
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: the CAPS.
    Cardiac Arrhythmia Pilot Study (CAPS) Investigators
    Am J Cardiol; 1988 Mar; 61(8):501-9. PubMed ID: 2894169
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and electrophysiologic effects of encainide for atrioventricular nodal reentrant tachycardia.
    Naccarelli GV; Jackman WM; Akhtar M; Rinkenberger RL; Friday KJ; Dougherty AH; Tchou P; Yeung-Lai-Wah JA
    Am J Cardiol; 1988 Dec; 62(19):31L-36L. PubMed ID: 3144165
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravenous 3-methoxy-O-desmethyl-encainide in reentrant supraventricular tachycardia: a randomized double-blind placebo-controlled trial in patients undergoing EP study.
    Ware DL; Lee JT; Murray KT; Hanyok JJ; Roden DM; Echt DS
    Pacing Clin Electrophysiol; 1991 Sep; 14(9):1343-50. PubMed ID: 1720527
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Possible contribution of encainide metabolites to the long-term antiarrhythmic efficacy of encainide.
    Winkle RA; Peters F; Kates RE; Harrison DC
    Am J Cardiol; 1983 Apr; 51(7):1182-8. PubMed ID: 6404150
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparisons of efficacy and tolerance of moricizine with other antiarrhythmic agents in the treatment of chronic ventricular arrhythmias.
    Anderson JL
    Am J Cardiol; 1990 Feb; 65(8):32D-40D. PubMed ID: 2106254
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Electrophysiological effects of encainide in man].
    Cassagneau B; Calazel J; Puel J; Massabuau P; Miquel JP; Bounhoure JP; Marin T; Narula OS
    Arch Mal Coeur Vaiss; 1984 Jun; 77(6):707-11. PubMed ID: 6431937
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of supraventricular arrhythmias with encainide.
    Pool PE
    Am J Cardiol; 1986 Aug; 58(5):55C-57C. PubMed ID: 3092621
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Possible atrial proarrhythmic effects of class 1C antiarrhythmic drugs.
    Feld GK; Chen PS; Nicod P; Fleck RP; Meyer D
    Am J Cardiol; 1990 Aug; 66(3):378-83. PubMed ID: 2114784
    [No Abstract]   [Full Text] [Related]  

  • 40. Antiarrhythmic efficacy of encainide in patients with refractory recurrent ventricular tachycardia.
    Mason JW; Peters FA
    Circulation; 1981 Mar; 63(3):670-5. PubMed ID: 6780234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.